MBX Biosciences Common Stock Accounts Payable

MBX Biosciences Common Stock (MBX) currently reports a accounts payable of $4.4M as of June 2026. That compares with $5.8M in the prior-year period — down 24.4% year over year. Use the charts on this page to explore MBX Biosciences Common Stock's accounts payable history and peer comparisons.

MBX Biosciences Common Stock's accounts payable decreased from $5.8M to $4.4M — a 24.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MBX Biosciences Common Stock reported $4.4M in accounts payable as of June 2026. That compares with $5.8M in the prior-year period — down 24.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $4.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MBX Biosciences Common Stock, and consider following MBX for alerts when major investors trade the stock.

MBX Biosciences Common Stock is classified in the Healthcare sector. On accounts payable, it currently shows $4.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBX with unrelated industries.